Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lentiviral gene therapy for newly diagnosed SCID-X1 infants
NCT01512888Phase 2Suspended
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Aug 2016
- Primary completion
- Aug 2026
- Modality
- Gene Editing, Gene Silencing, Hematopoietic Stem Cells
- Countries
- 1
01
Overview
A Phase 2 trial of MB-207 in X-linked severe combined immunodeficiency (X-SCID), sponsored by St. Jude Children's Research Hospital. Started Aug 2016; status: suspended.
02
Drugs
MB-207
03
Conditions
X-linked severe combined immunodeficiency (X-SCID)
Beyond the preview
Go deeper on NCT01512888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01512888.